

# Aik-Choon Tan

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8596381/aik-choon-tan-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

213 papers	9,613 citations	51 h-index	91 g-index
260 ext. papers	11,518 ext. citations	7.6 avg, IF	5.89 L-index

#	Paper	IF	Citations
213	Nlp63 regulates a common landscape of enhancer associated genes in non-small cell lung cancer.. <i>Nature Communications</i> , <b>2022</b> , 13, 614	17.4	0
212	MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells. <i>Journal of Leukocyte Biology</i> , <b>2021</b> , 110, 197-205	6.5	0
211	Uncovering drug repurposing candidates for head and neck cancers: insights from systematic pharmacogenomics data analysis.. <i>Scientific Reports</i> , <b>2021</b> , 11, 23933	4.9	1
210	88 Evidence of enhanced immune activation within the tumor microenvironment and the circulation of female patients with high-risk melanoma compared to males <b>2021</b> , 9, A96-A96		
209	87 Enhanced immunogenicity within the tumor microenvironment and the circulation of high-risk melanoma patients with unknown primary compared to those whose primary melanoma is known <b>2021</b> , 9, A95-A95		
208	Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	30
207	Novel Human-Derived Fusion NSCLC Cell Lines Have Heterogeneous Responses to RET Inhibitors and Differential Regulation of Downstream Signaling. <i>Molecular Pharmacology</i> , <b>2021</b> , 99, 435-447	4.3	1
206	A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer. <i>Npj Precision Oncology</i> , <b>2021</b> , 5, 41	9.8	1
205	Enabling Precision Medicine in Cancer Care Through a Molecular Data Warehouse: The Moffitt Experience. <i>JCO Clinical Cancer Informatics</i> , <b>2021</b> , 5, 561-569	5.2	1
204	Variant Calling in Next Generation Sequencing Data <b>2021</b> , 129-140		
203	Identification of RUNX1T1 as a potential epigenetic modifier in small-cell lung cancer. <i>Molecular Oncology</i> , <b>2021</b> , 15, 195-209	7.9	6
202	Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse Xenograft. <i>Molecular Cancer Research</i> , <b>2021</b> , 19, 346-357	6.6	2
201	Exogenous Thyroid Hormone Is Associated with Shortened Survival and Upregulation of High-Risk Gene Expression Profiles in Steroid Receptor-Positive Breast Cancers. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 585-597	12.9	4
200	Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma. <i>Molecular Cancer Therapeutics</i> , <b>2021</b> , 20, 2049-2060	6.1	2
199	Deep Learning of Histopathology Images at the Single Cell Level. <i>Frontiers in Artificial Intelligence</i> , <b>2021</b> , 4, 754641	3	2
198	Crowdsourced identification of multi-target kinase inhibitors for RET- and TAU- based disease: The Multi-Targeting Drug DREAM Challenge. <i>PLoS Computational Biology</i> , <b>2021</b> , 17, e1009302	5	4
197	Spontaneous cell fusions as a mechanism of parasexual recombination in tumour cell populations. <i>Nature Ecology and Evolution</i> , <b>2021</b> , 5, 379-391	12.3	12

196	Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma. <i>Molecular Carcinogenesis</i> , <b>2021</b> , 60, 138-150	5	2
195	Multimomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. <i>Genome Biology</i> , <b>2020</b> , 21, 271	18.3	13
194	Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures. <i>Nature Communications</i> , <b>2020</b> , 11, 2393	17.4	22
193	Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4633-4642	12.9	2
192	MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. <i>Cell Death and Disease</i> , <b>2020</b> , 11, 443	9.8	23
191	Induction of IRAK-M in melanoma induces caspase-3 dependent apoptosis by reducing TRAF6 and calpastatin levels. <i>Communications Biology</i> , <b>2020</b> , 3, 306	6.7	1
190	First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2020</b> , 19, 1598-1612	6.1	9
189	Loss of prdm1a accelerates melanoma onset and progression. <i>Molecular Carcinogenesis</i> , <b>2020</b> , 59, 1052-1063	5.6	4
188	Leptomeningeal Metastasis from Adrenocortical Carcinoma: A Case Report. <i>Journal of the Endocrine Society</i> , <b>2020</b> , 4, bvaa017	0.4	1
187	Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway. <i>ELife</i> , <b>2020</b> , 9,	8.9	9
186	Effects of prexasertib, a CHK1 inhibitor, in the immune microenvironment of head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e18541-e18541	2.2	0
185	The mutational landscape of mucosal melanoma. <i>Seminars in Cancer Biology</i> , <b>2020</b> , 61, 139-148	12.7	46
184	Inhibiting Translation Elongation with SVC112 Suppresses Cancer Stem Cells and Inhibits Growth in Head and Neck Squamous Carcinoma. <i>Cancer Research</i> , <b>2020</b> , 80, 1183-1198	10.1	7
183	Role of mTOR As an Essential Kinase in SCLC. <i>Journal of Thoracic Oncology</i> , <b>2020</b> , 15, 1522-1534	8.9	4
182	Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy. <i>Cancers</i> , <b>2020</b> , 12,	6.6	8
181	Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 1474-1485	12.9	24
180	First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits $\beta$ Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2019</b> , 18, 1916-1925	6.1	9
179	Transcatheter aortic valve replacements alter circulating serum factors to mediate myofibroblast deactivation. <i>Science Translational Medicine</i> , <b>2019</b> , 11,	17.5	26

178	Clinical implications of ALDH1A1 and ALDH1A3 mRNA expression in melanoma subtypes. <i>Chemico-Biological Interactions</i> , <b>2019</b> , 314, 108822	5	10
177	ReSimNet: drug response similarity prediction using Siamese neural networks. <i>Bioinformatics</i> , <b>2019</b> , 35, 5249-5256	7.2	18
176	IFITM3 knockdown reduces the expression of CCND1 and CDK4 and suppresses the growth of oral squamous cell carcinoma cells. <i>Cellular Oncology (Dordrecht)</i> , <b>2019</b> , 42, 477-490	7.2	15
175	Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 3141-3151	12.9	50
174	Expanding the Connectivity Map Concept as the Functional Look-Up Table for Systems Biology. <i>Advances in Molecular Pathology</i> , <b>2019</b> , 2, 201-213	0.3	
173	The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib. <i>Expert Review of Anticancer Therapy</i> , <b>2019</b> , 19, 971-991	3.5	18
172	Defining the role of RUNX1T1 in "combined" small cell lung cancer.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, e20101-e20101	2.2	1
171	Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines. <i>Molecular Pharmacology</i> , <b>2019</b> , 96, 862-870	4.3	4
170	Large expert-curated database for benchmarking document similarity detection in biomedical literature search. <i>Database: the Journal of Biological Databases and Curation</i> , <b>2019</b> , 2019,	5	4
169	Reversal of Triple-Negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immunosuppression. <i>Molecular Cancer Research</i> , <b>2019</b> , 17, 30-41	6.6	30
168	Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis. <i>Oncogene</i> , <b>2019</b> , 38, 2565-2579	9.2	11
167	Exploring the molecular mechanisms of Traditional Chinese Medicine components using gene expression signatures and connectivity map. <i>Computer Methods and Programs in Biomedicine</i> , <b>2019</b> , 174, 33-40	6.9	15
166	GENIPAC: A Genomic Information Portal for Head and Neck Cancer Cell Systems. <i>Journal of Dental Research</i> , <b>2018</b> , 97, 909-916	8.1	5
165	PAGER 2.0: an update to the pathway, annotated-list and gene-signature electronic repository for Human Network Biology. <i>Nucleic Acids Research</i> , <b>2018</b> , 46, D668-D676	20.1	10
164	Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 3059-3068	12.9	211
163	Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer. <i>BMC Cancer</i> , <b>2018</b> , 18, 136	4.8	6
162	Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 2935-2943	12.9	15
161	ALK Inhibitor Response in Melanomas Expressing Fusions and Alternate Isoforms. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 222-231	6.1	24

160	GSEA-InContext: identifying novel and common patterns in expression experiments. <i>Bioinformatics</i> , <b>2018</b> , 34, i555-i564	7.2	54
159	Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Related Lesions. <i>Journal of Thoracic Oncology</i> , <b>2018</b> , 13, 1496-1507	8.9	18
158	CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 2257-2265	6.1	23
157	Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5368-5380	12.9	120
156	IMPACT web portal: oncology database integrating molecular profiles with actionable therapeutics. <i>BMC Medical Genomics</i> , <b>2018</b> , 11, 26	3.7	3
155	Deep learning of mutation-gene-drug relations from the literature. <i>BMC Bioinformatics</i> , <b>2018</b> , 19, 21	3.6	28
154	AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. <i>Cell Stem Cell</i> , <b>2018</b> , 23, 86-100.e6	18	116
153	The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth. <i>Oncotarget</i> , <b>2018</b> , 9, 33110-33123	3.3	21
152	A Pilot Study of Biomedical Text Comprehension using an Attention-Based Deep Neural Reader: Design and Experimental Analysis. <i>JMIR Medical Informatics</i> , <b>2018</b> , 6, e2	3.6	5
151	ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. <i>Oncotarget</i> , <b>2018</b> , 9, 8823-8835	3.3	15
150	CDK1 Interacts with Sox2 and Promotes Tumor Initiation in Human Melanoma. <i>Cancer Research</i> , <b>2018</b> , 78, 6561-6574	10.1	64
149	A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer. <i>Oncologist</i> , <b>2018</b> , 23, 1409-e140	5.7	4
148	Systems Pharmacology-Based Approach of Connecting Disease Genes in Genome-Wide Association Studies with Traditional Chinese Medicine. <i>International Journal of Genomics</i> , <b>2018</b> , 2018, 7697356	2.5	6
147	Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4949-4959	12.9	39
146	Context-dependent role for chromatin remodeling component PBRM1/BAF180 in clear cell renal cell carcinoma. <i>Oncogenesis</i> , <b>2017</b> , 6, e287	6.6	16
145	A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance. <i>Molecular Cancer Research</i> , <b>2017</b> , 15, 382-394	6.6	7
144	Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling. <i>Molecular Cancer Therapeutics</i> , <b>2017</b> , 16, 1623-1633	6.1	44
143	Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma. <i>Melanoma Research</i> , <b>2017</b> , 27, 189-199	3.3	86

142	Co-dependency of PKC $\delta$ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer. <i>Oncogene</i> , <b>2017</b> , 36, 4370-4378	9.2	10
141	Brusatol overcomes chemoresistance through inhibition of protein translation. <i>Molecular Carcinogenesis</i> , <b>2017</b> , 56, 1493-1500	5	64
140	Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response. <i>Journal of Biological Chemistry</i> , <b>2017</b> , 292, 15105-15120	5.4	40
139	DeSigN: connecting gene expression with therapeutics for drug repurposing and development. <i>BMC Genomics</i> , <b>2017</b> , 18, 934	4.5	45
138	Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924). <i>Investigational New Drugs</i> , <b>2017</b> , 35, 11-25	4.3	12
137	Exploiting receptor tyrosine kinase co-activation for cancer therapy. <i>Drug Discovery Today</i> , <b>2017</b> , 22, 72-84	8.8	21
136	AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 1531-1541	12.9	38
135	Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 1710-1721	12.9	101
134	Kinase gene fusions in defined subsets of melanoma. <i>Pigment Cell and Melanoma Research</i> , <b>2017</b> , 30, 53-62	4.5	29
133	Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	70
132	Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2017</b> , 76, 779-788	3.1	39
131	Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , <b>2017</b> , 7, 94	5.3	16
130	Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model. <i>PLoS ONE</i> , <b>2017</b> , 12, e0187173	3.7	14
129	XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer. <i>Oncogene</i> , <b>2016</b> , 35, 290-300	9.2	94
128	Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. <i>Rheumatology</i> , <b>2016</b> , 55, 2220-2229	3.9	56
127	Big Data Mining and Adverse Event Pattern Analysis in Clinical Drug Trials. <i>Assay and Drug Development Technologies</i> , <b>2016</b> , 14, 557-566	2.1	7
126	Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors. <i>Science Signaling</i> , <b>2016</b> , 9, rs12	8.8	19
125	Dual Targeting of PDGFR $\beta$ and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors. <i>Cell Reports</i> , <b>2016</b> , 17, 1265-1275	10.6	36



124	Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies. <i>Journal of Visualized Experiments</i> , <b>2016</b> ,	1.6	10
123	A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma. <i>Oral Oncology</i> , <b>2016</b> , 53, 74-9	4.4	22
122	Mammary epithelial cell phagocytosis downstream of TGF- $\beta$ is characterized by adherens junction reorganization. <i>Cell Death and Differentiation</i> , <b>2016</b> , 23, 185-96	12.7	19
121	Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 50290-50301	3.3	19
120	PKC $\zeta$ regulates integrin $\alpha$ $\beta$ expression and transformed growth of K-ras dependent lung cancer cells. <i>Oncotarget</i> , <b>2016</b> , 7, 17905-19	3.3	11
119	Genetically-defined novel oral squamous cell carcinoma cell lines for the development of molecular therapies. <i>Oncotarget</i> , <b>2016</b> , 7, 27802-18	3.3	33
118	Emerging transcriptional landscape and putative therapeutic targets in young patients with metastatic colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 605-605	2.2	
117	Emerging genomic landscape and therapeutic targets in young patients with colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3589-3589	2.2	
116	Genomic distinctions between colon and rectal cancer in young patients.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3574-3574	2.2	
115	Systematic analysis of tumour cell-extracellular matrix adhesion identifies independent prognostic factors in breast cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 62939-62953	3.3	19
114	A Survey of Computational Tools to Analyze and Interpret Whole Exome Sequencing Data. <i>International Journal of Genomics</i> , <b>2016</b> , 2016, 7983236	2.5	23
113	BEST: Next-Generation Biomedical Entity Search Tool for Knowledge Discovery from Biomedical Literature. <i>PLoS ONE</i> , <b>2016</b> , 11, e0164680	3.7	54
112	Integrating heterogeneous drug sensitivity data from cancer pharmacogenomic studies. <i>Oncotarget</i> , <b>2016</b> , 7, 51619-51625	3.3	25
111	BRONCO: Biomedical entity Relation ONcology Corpus for extracting gene-variant-disease-drug relations. <i>Database: the Journal of Biological Databases and Curation</i> , <b>2016</b> , 2016,	5	22
110	IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples. <i>Journal of the American Medical Informatics Association: JAMIA</i> , <b>2016</b> , 23, 721-30	8.6	34
109	The Mitogen-Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor Dasatinib in Thyroid Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 1952-63	6.1	14
108	ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, E6669-E6678	11.5	52
107	HiPub: translating PubMed and PMC texts to networks for knowledge discovery. <i>Bioinformatics</i> , <b>2016</b> , 32, 2886-8	7.2	12

106	Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. <i>Molecular Cancer Therapeutics</i> , <b>2016</b> , 15, 2314-2322	6.1	51
105	A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer. <i>International Journal of Cancer</i> , <b>2016</b> , 138, 195-205	7.5	24
104	Twist1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation. <i>Cancer Research</i> , <b>2015</b> , 75, 1908-21	10.1	48
103	Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data. <i>Bioinformatics</i> , <b>2015</b> , 31, 3799-806	7.2	8
102	Systems biology approaches for advancing the discovery of effective drug combinations. <i>Journal of Cheminformatics</i> , <b>2015</b> , 7, 7	8.6	79
101	RIP1 negatively regulates basal autophagic flux through TFEB to control sensitivity to apoptosis. <i>EMBO Reports</i> , <b>2015</b> , 16, 700-8	6.5	49
100	p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 1117-29	6.1	28
99	Comparative Haploid Genetic Screens Reveal Divergent Pathways in the Biogenesis and Trafficking of Glycophosphatidylinositol-Anchored Proteins. <i>Cell Reports</i> , <b>2015</b> , 11, 1727-36	10.6	27
98	Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC. <i>Cancer Research</i> , <b>2015</b> , 75, 4398-406	10.1	45
97	Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants. <i>Molecular Cancer Therapeutics</i> , <b>2015</b> , 14, 317-25	6.1	27
96	An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer. <i>BMC Genomics</i> , <b>2015</b> , 16 Suppl 12, S2	4.5	6
95	An Inducible TGF- $\beta$ -TGFR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases. <i>PLoS ONE</i> , <b>2015</b> , 10, e0123600	3.7	4
94	Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models. <i>Frontiers in Pharmacology</i> , <b>2015</b> , 6, 120	5.6	16
93	DSigDB: drug signatures database for gene set analysis. <i>Bioinformatics</i> , <b>2015</b> , 31, 3069-71	7.2	123
92	FGFR1 Expression Levels Predict BGJ398 Sensitivity of FGFR1-Dependent Head and Neck Squamous Cell Cancers. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 4356-64	12.9	62
91	Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. <i>International Journal of Cancer</i> , <b>2015</b> , 136, 1967-75	7.5	35
90	The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p. <i>Nature Communications</i> , <b>2015</b> , 6, 10077	17.4	33
89	Contrasting roles for C/EBP $\beta$ and Notch in irradiation-induced multipotent hematopoietic progenitor cell defects. <i>Stem Cells</i> , <b>2015</b> , 33, 1345-58	5.8	15



88	Aging-associated inflammation promotes selection for adaptive oncogenic events in B cell progenitors. <i>Journal of Clinical Investigation</i> , <b>2015</b> , 125, 4666-80	15.9	90
87	Emerging transcriptional landscape and putative therapeutic strategies in young patients with metastatic colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e14627-e14627	2.2	2
86	iCOSSy: An Online Tool for Context-Specific Subnetwork Discovery from Gene Expression Data. <i>PLoS ONE</i> , <b>2015</b> , 10, e0131656	3.7	1
85	Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts. <i>Oncotarget</i> , <b>2015</b> , 6, 34561-72	3.3	10
84	Parkinsons Disease-related Circulating microRNA Biomarkers Validation Study. <i>AIMS Medical Science</i> , <b>2015</b> , 2, 7-14	0.4	4
83	BEReX: Biomedical Entity-Relationship eXplorer. <i>Bioinformatics</i> , <b>2014</b> , 30, 135-6	7.2	4
82	Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy. <i>Bioinformatics</i> , <b>2014</b> , 30, 2393-8	7.2	18
81	Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer. <i>Molecular Cancer</i> , <b>2014</b> , 13, 62	42.1	67
80	Long term storage of dry versus frozen RNA for next generation molecular studies. <i>PLoS ONE</i> , <b>2014</b> , 9, e111827	3.7	23
79	Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer. <i>PLoS ONE</i> , <b>2014</b> , 9, e113037	3.7	33
78	FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 3299-309	12.9	127
77	Homeoprotein Six2 promotes breast cancer metastasis via transcriptional and epigenetic control of E-cadherin expression. <i>Cancer Research</i> , <b>2014</b> , 74, 7357-70	10.1	33
76	Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 1656-65	12.9	43
75	Automatic context-specific subnetwork discovery from large interaction networks. <i>PLoS ONE</i> , <b>2014</b> , 9, e84227	3.7	9
74	RNA-seq and KRAS mutational status in ascitic pancreatic cancer cells: Novel results and distinct subsets.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e15214-e15214	2.2	1
73	Genomic signatures of pregnancy-associated breast cancer epithelia and stroma and their regulation by estrogens and progesterone. <i>Hormones and Cancer</i> , <b>2013</b> , 4, 140-53	5	30
72	Collagen architecture in pregnancy-induced protection from breast cancer. <i>Journal of Cell Science</i> , <b>2013</b> , 126, 4108-10	5.3	72
71	Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia. <i>Blood</i> , <b>2013</b> , 122, 1599-609	2.2	43

70	The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas. <i>Molecular Cancer Therapeutics</i> , <b>2013</b> , 12, 1994-2005	6.1	22
69	K-Map: connecting kinases with therapeutics for drug repurposing and development. <i>Human Genomics</i> , <b>2013</b> , 7, 20	6.8	20
68	A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. <i>Molecular Oncology</i> , <b>2013</b> , 7, 776-90	7.9	116
67	A genetic screen identifies TCF3/E2A and TRIAP1 as pathway-specific regulators of the cellular response to p53 activation. <i>Cell Reports</i> , <b>2013</b> , 3, 1346-54	10.6	45
66	Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 4149-62	12.9	58
65	Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 291-303	12.9	34
64	Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 6219-29	12.9	45
63	Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a $\beta$ -secretase inhibitor, in a preclinical colorectal explant model. <i>British Journal of Cancer</i> , <b>2013</b> , 109, 667-75	8.7	30
62	A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. <i>Oncogenesis</i> , <b>2013</b> , 2, e39	6.6	179
61	A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines. <i>Molecular Pharmacology</i> , <b>2013</b> , 83, 882-93	4.3	36
60	From bench to bedside: lessons learned in translating preclinical studies in cancer drug development. <i>Journal of the National Cancer Institute</i> , <b>2013</b> , 105, 1441-56	9.7	41
59	MERTK receptor tyrosine kinase is a therapeutic target in melanoma. <i>Journal of Clinical Investigation</i> , <b>2013</b> , 123, 2257-67	15.9	105
58	DNA methylation profiling revealed promoter hypermethylation-induced silencing of p16, DDAH2 and DUSP1 in primary oral squamous cell carcinoma. <i>International Journal of Medical Sciences</i> , <b>2013</b> , 10, 1727-39	3.7	51
57	Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. <i>PLoS ONE</i> , <b>2013</b> , 8, e82236	3.7	85
56	Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal Cancer. <i>Frontiers in Pharmacology</i> , <b>2013</b> , 4, 22	5.6	26
55	Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. <i>Frontiers in Pharmacology</i> , <b>2013</b> , 4, 35	5.6	25
54	Integrating Omics Data for Quantitative and Systems Pharmacology in Translational Oncology <b>2013</b> , 187-206		1
53	The miR-106b-25 cluster targets Smad7, activates TGF- $\beta$ signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. <i>Oncogene</i> , <b>2012</b> , 31, 5162-71	9.2	246

52	Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. <i>Cancer Research</i> , <b>2012</b> , 72, 4154-64	10.1	105
51	Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2012</b> , 109, 2742-7	11.5	80
50	Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer. <i>Cancer Medicine</i> , <b>2012</b> , 1, 207-14	11.8	12
49	ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. <i>Nature Chemical Biology</i> , <b>2012</b> , 8, 646-54	11.7	57
48	ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a secretase inhibitor and irinotecan in colorectal cancer. <i>Molecular Oncology</i> , <b>2012</b> , 6, 370-81	7.9	28
47	Plasma-based circulating MicroRNA biomarkers for Parkinson's disease. <i>Journal of Parkinsons Disease</i> , <b>2012</b> , 2, 321-31	5.3	132
46	Patient-derived tumour xenografts as models for oncology drug development. <i>Nature Reviews Clinical Oncology</i> , <b>2012</b> , 9, 338-50	19.4	900
45	Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia. <i>Leukemia</i> , <b>2012</b> , 26, 1266-76	10.7	61
44	Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells. <i>Cell Research</i> , <b>2012</b> , 22, 321-32	24.7	143
43	Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 1051-62	12.9	36
42	A DNA methylation fingerprint of 1628 human samples. <i>Genome Research</i> , <b>2012</b> , 22, 407-19	9.7	273
41	Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 2704-14	12.9	38
40	Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer. <i>Cancer Research</i> , <b>2012</b> , 72, 6490-501	10.1	41
39	BiNGS!SL-seq: a bioinformatics pipeline for the analysis and interpretation of deep sequencing genome-wide synthetic lethal screen. <i>Methods in Molecular Biology</i> , <b>2012</b> , 802, 389-98	1.4	24
38	Employing gene set top scoring pairs to identify deregulated pathway-signatures in dilated cardiomyopathy from integrated microarray gene expression data. <i>Methods in Molecular Biology</i> , <b>2012</b> , 802, 345-61	1.4	1
37	Abstract B35: Alternate receptor tyrosine kinases provide protection from FGFR inhibition in HNSCC cells as identified by genome-wide shRNA screening. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, B35-B35	12.9	
36	Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. <i>Nature Medicine</i> , <b>2011</b> , 17, 860-6	50.5	553
35	Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. <i>Nature Medicine</i> , <b>2011</b> , 17, 1109-15	50.5	256

34	A short survey of computational analysis methods in analysing ChIP-seq data. <i>Human Genomics</i> , <b>2011</b> , 5, 117-23	6.8	15
33	MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML. <i>British Journal of Haematology</i> , <b>2011</b> , 153, 753-7	4.5	30
32	Host response transcriptional profiling reveals extracellular components and ABC (ATP-binding cassette) transporters gene enrichment in typhoid fever-infected Nigerian children. <i>BMC Infectious Diseases</i> , <b>2011</b> , 11, 241	4	10
31	Confident predictability: identifying reliable gene expression patterns for individualized tumor classification using a local minimax kernel algorithm. <i>BMC Medical Genomics</i> , <b>2011</b> , 4, 10	3.7	3
30	Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 5793-800	12.9	175
29	Genome-Wide shRNA Screen Identifies WEE1 As a Critical Mediator of Cell Fate and Novel Therapeutic Target in AML,. <i>Blood</i> , <b>2011</b> , 118, 3503-3503	2.2	
28	Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer. <i>British Journal of Cancer</i> , <b>2010</b> , 103, 649-55	8.7	61
27	Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. <i>Molecular Cancer Therapeutics</i> , <b>2010</b> , 9, 3351-62	6.1	66
26	Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 4165-77	12.9	37
25	Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 5581-90	12.9	284
24	Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 3193-204	12.9	65
23	Redox-dependent Brca1 transcriptional regulation by an NADH-sensor CtBP1. <i>Oncogene</i> , <b>2010</b> , 29, 6603-12	3.2	29
22	The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 5436-46	12.9	33
21	Novel agents in the treatment of metastatic colorectal cancer. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2010</b> , 16, 273-82	2.2	6
20	A survey of statistical software for analysing RNA-seq data. <i>Human Genomics</i> , <b>2010</b> , 5, 56-60	6.8	21
19	Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. <i>Molecular Cancer Therapeutics</i> , <b>2009</b> , 8, 1484-93	6.1	37
18	A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. <i>Cancer Biology and Therapy</i> , <b>2009</b> , 8, 2013-24	4.6	96
17	Identification of novel serological biomarkers for inflammatory bowel disease using Escherichia coli proteome chip. <i>Molecular and Cellular Proteomics</i> , <b>2009</b> , 8, 1765-76	7.6	53

16	Quantitative proteomic analysis of ovarian cancer cells identified mitochondrial proteins associated with Paclitaxel resistance. <i>Proteomics - Clinical Applications</i> , <b>2009</b> , 3, 1288-95	3.1	20
15	Characterizing DNA methylation patterns in pancreatic cancer genome. <i>Molecular Oncology</i> , <b>2009</b> , 3, 425-38	7.9	115
14	Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 4138-46	12.9	76
13	The AML Prognostic Marker, AF1q, Is Directly Regulated by MiR-29b.. <i>Blood</i> , <b>2009</b> , 114, 2603-2603	2.2	
12	Merging microarray data from separate breast cancer studies provides a robust prognostic test. <i>BMC Bioinformatics</i> , <b>2008</b> , 9, 125	3.6	69
11	Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. <i>Cancer Research</i> , <b>2008</b> , 68, 2841-9	10.1	84
10	Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. <i>Molecular Cancer Therapeutics</i> , <b>2008</b> , 7, 3275-84	6.1	70
9	Allele-specific expression in the germline of patients with familial pancreatic cancer: an unbiased approach to cancer gene discovery. <i>Cancer Biology and Therapy</i> , <b>2008</b> , 7, 135-44	4.6	37
8	<b>2008</b> ,		4
7	Simple decision rules for classifying human cancers from gene expression profiles. <i>Bioinformatics</i> , <b>2005</b> , 21, 3896-904	7.2	287
6	Robust prostate cancer marker genes emerge from direct integration of inter-study microarray data. <i>Bioinformatics</i> , <b>2005</b> , 21, 3905-11	7.2	108
5	MSAT: a multiple sequence alignment tool based on TOPS. <i>Applied Bioinformatics</i> , <b>2004</b> , 3, 149-58		4
4	An Assessment of Feature Relevance in Predicting Protein Function from Sequence. <i>Lecture Notes in Computer Science</i> , <b>2004</b> , 52-57	0.9	2
3	Multi-class protein fold classification using a new ensemble machine learning approach. <i>Genome Informatics</i> , <b>2003</b> , 14, 206-17		26
2	Spontaneous Cell Fusions as a Mechanism of Parasexual Recombination in Tumor Cell Populations		2
1	Loss of prdm1a accelerates melanoma onset and progression		2